Study of the Effects of Chemotherapy on Memory and Other Mental Functions in Women With Breast Cancer

This study has been completed.

Sponsor:

Collaborator:

Canadian Breast Cancer Foundation

Information provided by:

Ottawa Hospital Research Institute

ClinicalTrials.gov Identifier:

NCT00260975

First received: November 30, 2005

Last updated: August 23, 2010

Last verified: August 2010

History of Changes

Purpose

Many breast cancer patients treated with chemotherapy complain of problems with concentration and memory. This has been referred to as "chemo fog". The current study is investigating this phenomenon by measuring patients' mental function prior to and after exposure to chemotherapy, and by comparing mental function in those patients who receive chemotherapy and those who do not.

Condition
Breast Cancer


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	A Prospective, Longitudinal Investigation of the Neuropsychological and Psychosocial Effects of Cancer Therapy

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer

U.S. FDA Resources

Further study details as provided by Ottawa Hospital Research Institute:


Estimated Enrollment:	150
Study Start Date:	June 2001
Study Completion Date:	February 2008
Primary Completion Date:	February 2008 (Final data collection date for primary outcome measure)

Detailed Description:

Many breast cancer patients treated with chemotherapy complain of problems with concentration and memory. This has been referred to as "chemo fog". The current study will investigate this phenomenon by measuring neuropsychological functioning in early stage breast cancer patients prior to and after exposure to chemotherapy, and by comparing change in cognitive function in these patients who receive chemotherapy to similar breast cancer patients receiving hormonal therapy only, and to healthy women without breast cancer.

Eligibility


Ages Eligible for Study:	50 Years to 65 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Breast Cancer

Criteria

Inclusion Criteria:

stage I or II breast cancer; woman; 50-65 years old; post-menopausal

Exclusion Criteria:

history of previous cancer or chemotherapy; significant neurological or psychiatric history

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00260975

Sponsors and Collaborators

Ottawa Hospital Research Institute

Canadian Breast Cancer Foundation

Investigators


Principal Investigator:	Barbara Collins	OHRI

More Information


Responsible Party:	Dr. Barbara Collins, Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:	NCT00260975 History of Changes
Other Study ID Numbers:	1999232-01H
Study First Received:	November 30, 2005
Last Updated:	August 23, 2010

Keywords provided by Ottawa Hospital Research Institute:


breast cancer chemotherapy hormonal therapy cognitive function chemo fog

Additional relevant MeSH terms:


Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases

ClinicalTrials.gov processed this record on June 27, 2017

To Top